...
...
Next Story

Centre restricts sale of cough syrups sans licence in villages

India's health ministry has removed cough syrups from Schedule K, mandating sales only through licensed pharmacies to combat misuse and contamination.

Published on: Jun 17, 2026, 06:18:18 IST
Advertisement

The Union ministry of health and family welfare has removed cough syrups from the so-called Schedule K, which exempts medicines from manufacturing, distribution, and retail licensing regulations that are otherwise mandatory for drugs -- a move widely seen as an effort to clamp down on the manufacture of sub-par cough syrups , and their sales, in villages and small towns, by establishments that do not process a drug retailing licence.

Centre restricts sale of cough syrups sans licence in villages
Centre restricts sale of cough syrups sans licence in villages

There have been reports of rampant misuse of cough syrups across urban and rural India, with people seeing them as a cheaper, and more accessible option to liquor and drugs. There have also been reports of people, especially children, dying from the use of sub-par cough syrups.

The health ministry gazette notified the removal of cough syrups from its list of schedule K drugs (those that can be sold over the counter and by retail establishments other than pharmacies also); this means only pharmacies can now sell cough syrups.

The health ministry announced the change in a statement.

To be sure, monitoring is lax, and even Schedule H drugs, which can only be sold on prescription are freely available across the counter, albeit only at pharmacies. In many towns and villages and even some citiesa, cough syrups are also freely available at many stores.

This exemption will no longer be available for cough syrups. “Consequently, the sale and dispensing of cough syrups in smaller villages will now be required to take place only through duly licensed pharmacies in accordance with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules framed thereunder,” said the health ministry’s statement.

The sale of cough syrups manufactured in India has also been marred by controversies related to contamination.

Last year, at least 22 children were killed in India, mainly in Rajasthan, due consumption of contaminated cough syrup. The cough syrup was found to be contaminated with contaminated diethylene glycol (DEG), a toxic industrial solvent used in brake fluid and antifreeze etc. In laboratory tests, the concentration of DEG was found to be hundreds of times above the permissible limit of 0.1%.

In the past, India-made cough syrups have been linked to the deaths of children in The Gambia and Uzbekistan.

The latest move is also prompted by a desire to crack down on the use of cough syrups as a substitute for narcotics; in recent years, the Border Security Force has seized huge quantities of India-made cough syrups being smuggled to Bangladesh.

“The amendment has been undertaken to strengthen regulatory oversight of syrup formulations and to align the exemption framework with contemporary public health and safety requirements. The measure is expected to promote responsible distribution and sale of cough syrups while ensuring greater compliance with regulatory standards across the country,” said the health ministry, asking manufacturers, distributors, and retailers dealing with cough syrups to ensure strict adherence to the applicable licensing and regulatory requirements under the Drugs & Cosmetics Act.

 
ABOUT THE AUTHOR
Rhythma Kaul

Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.

Get the latest India News, breaking headlines and real-time updates from across the country. Stay informed about politics, government policies, crime, weather and major national developments.
Get the latest India News, breaking headlines and real-time updates from across the country. Stay informed about politics, government policies, crime, weather and major national developments.
SHARE THIS ARTICLE ON
Hindustantimes wants to start sending you push notifications. Click allow to subscribe